Use of Transcranial Doppler as a Biomarker of CAR T Cell–Related Neurotoxicity
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 4, 2020
- Accepted June 24, 2021
- First Published August 9, 2021.
Article Versions
- Previous version (August 9, 2021 - 12:48).
- You are viewing the most recent version of this article.
Author Disclosures
- Kathryn B. Holroyd, MD*,
- Daniel B. Rubin, MD, PhD* (drubin4{at}mgh.harvard.edu),
- Sarah LaRose, BS (slmichaud{at}bwh.harvard.edu),
- Andrew Monk, BS (andrewdmonk{at}gmail.com),
- Sarah Nikiforow, MD, PhD (sarah_nikiforow{at}dfci.harvard.edu),
- Caron Jacobson, MD (caron_jacobson{at}dfci.harvard.edu) and
- Henrikas Vaitkevicius, MD (aa0374{at}gmail.com)
- Kathryn B. Holroyd, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel B. Rubin, MD, PhD* (drubin4{at}mgh.harvard.edu),
(1) Celgene/Bristol-Myers Squibb
NONE
NONE
NONE
(1) System and Method for Determining Treatment Outcomes for Neurological Disorders Based on Functional Connectivity Parameters
NONE
(1) Massachusetts General Hospital, Neurologist, 2020-present
NONE
NONE
NONE
NONE
NONE
NINDS Grant 5R25NS065743-12, Trainee, 2017-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah LaRose, BS (slmichaud{at}bwh.harvard.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew Monk, BS (andrewdmonk{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah Nikiforow, MD, PhD (sarah_nikiforow{at}dfci.harvard.edu),
Ad hoc advisory boards with Kite/Gilead, Novartis and Iovance
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Caron Jacobson, MD (caron_jacobson{at}dfci.harvard.edu) and
Lonza (SAB)
NONE
Kite, Novartis, BMS/Celgene, Lonza, Precision Biosciences, bluebird bio, Epizyme
Blood Advances - editorial advisory board
NONE
NONE
NONE
Kite, Novartis, BMS/Celgene, Lonza, Nkarta, Precision Biosciences, Abbvie, Bluebird Bio, Epizyme
AXIS, Clinical Care Options
NONE
NONE
Kite, Pfizer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henrikas Vaitkevicius, MD (aa0374{at}gmail.com)
Marinus Pharmaceuticals Inc.
NONE
NONE
NONE
NONE
NONE
Marinus Pharmaceuticals Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (KBH, SL, AM, HV), Brigham and Women's Hospital, Harvard Medical School, Boston; Department of Neurology (DBR), Massachusetts General Hospital, Harvard Medical School, Boston; and Department of Medical Oncology (SN, CJ), Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
- Correspondence
Dr. Holroyd kholroyd{at}partners.org
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.